Simple jQuery Dropdowns
Please use this identifier to cite or link to this item:
Title: The measurement of drug-induced interferon γ-releasing cells and lymphocyte proliferation in severe cutaneous adverse reactions
Authors: N. Suthumchai
Y. Srinoulprasert
P. Thantiworasit
P. Rerknimitr
P. Tuchinda
L. Chularojanamontri
T. Rerkpattanapipat
K. Chanprapaph
W. Disphanurat
P. Chakkavittumrong
N. Tovanabutra
C. Srisuttiyakorn
C. Sukasem
J. Klaewsongkram
Chulalongkorn University
King Chulalongkorn Memorial Hospital, Faculty of Medicine Chulalongkorn University
Faculty of Medicine, Ramathibodi Hospital, Mahidol University
Faculty of Medicine, Thammasat University
Faculty of Medicine, Siriraj Hospital, Mahidol University
Phramongkutklao College of Medicine
Chiang Mai University
Keywords: Medicine
Issue Date: 1-Jun-2018
Citation: Journal of the European Academy of Dermatology and Venereology. Vol.32, No.6 (2018), 992-998
Abstract: © 2018 European Academy of Dermatology and Venereology Background: The lymphocyte transformation test (LTT) is a standard laboratory method to identify culprit drugs in patients with a history of drug-induced non-immediate hypersensitivity and is mainly performed during the recovery phase. The measurement of drug-specific interferon γ (IFN-γ)-releasing cells has been introduced to confirm culprit drugs, even during the acute phase of drug allergy. Objectives: This study aimed to evaluate the capability of the enzyme-linked immunospot assay (ELISpot) to detect drug-specific IFN-γ-releasing cells during the acute phase and the capability of LTT to identify culprit drugs during the recovery phase in patients presenting with severe cutaneous adverse reactions (SCARs). Methods: Peripheral blood mononuclear cells (PBMCs) from 23 SCAR patients were collected during the acute and recovery phases and assayed for drug-specific IFN-γ-releasing cells and lymphocyte proliferation, respectively. Results: Drug-specific IFN-γ-releasing cells were detectable in 73.9% of SCAR subjects (55.6% and 85.7% in patients who were and were not taking systemic steroids, respectively), whereas LTT results were positive in 52.2% of SCAR subjects. The frequencies of drug-specific IFN-γ-releasing cells were significantly higher in patients with positive LTT than in those with negative LTT (260.1 ± 110.0 and 46.6 ± 20.7 cells/106 PBMCs, P = 0.01). A significant correlation between the results of the IFN-γ ELISpot assay and LTT was demonstrated (r = 0.65, P value <0.01). Conclusion: The IFN-γ ELISpot assay could be a useful tool to identify culprit drugs in SCAR patients when culprit drug identification is urgently needed during the acute phase of drug allergy.
ISSN: 14683083
Appears in Collections:Scopus 2018

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.